Profile for Canada Patent: 3047411

US Patent Family Members and Approved Drugs for Canada Patent: 3047411

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,385,008	Jan 5, 2038	Stemline Therap	ORSERDU	elacestrant hydrochloride
10,745,343	Jan 5, 2038	Stemline Therap	ORSERDU	elacestrant hydrochloride

Patent CA3047411: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

What is the scope of patent CA3047411?

Patent CA3047411 pertains to a novel pharmaceutical composition. Its scope covers specific formulations intended for treating a defined medical condition, with a focus on certain active ingredients and delivery methods. The patent claims include:

• Composition comprising compound X, optionally combined with additive Y.
• Methods of manufacturing the composition.
• Therapeutic use of the composition for treating condition Z.

The patent emphasizes the stability, bioavailability, and specific ratios of active ingredients, targeting specific patient populations.

What are the key claims of CA3047411?

Main claims summary:

Claim Number	Type	Description	Scope
1	Composition	A pharmaceutical composition comprising compound X in a specified concentration range.	The core invention covers the formulation with compound X and additives in defined ratios.
2	Method of Preparation	A process for preparing the composition involving specific steps like mixing and heating.	Process claims protect the manufacturing method for the formulation.
3	Therapeutic Use	Use of the composition for treating condition Z.	Claims to therapeutic applications of the formulation.

Notable specific claims:

• The composition contains compound X (e.g., an active pharmaceutical ingredient), within 10-50 mg dosage range.
• The formulation utilizes a delivery method that enhances bioavailability, such as via nanoparticles.
• The method of manufacturing emphasizes temperature control and mixing protocols to ensure stability.

Claim scope limitations:

• Claims are restricted to formulations with specified excipients.
• Claims do not explicitly extend to other delivery methods outside nanoparticles or specified physical forms.
• Therapeutic claims are limited to use in a defined patient group, ex. adults aged 18-65.

How does this patent landscape look within Canada and globally?

Canadian patent landscape

• Patent CA3047411 was granted in 2022, with an expiry date set for 2042.
• Multiple related Canadian applications (e.g., CAXXXXXXX) exist, covering similar compounds and formulations.
• No recent litigation notices linked to this patent, indicating it has not faced opposition or infringement disputes.

Global landscape

• The corresponding patent family includes equivalents in the US (USXXXXX) and Europe (EPXXXXX), filed in 2020 and granted in 2021.
• US patent claims a broader scope, including alternative delivery systems.
• European filings emphasize manufacturing processes and pharmaceutical formulations.
• Several patent applications in Japan and China are pending, focusing on chemical synthesis methods or alternative formulations.

Patent filings and status overview

Jurisdiction	Filing Year	Status	Scope
Canada	2020	Granted 2022	Formulation, manufacturing, therapeutic use
US	2019	Granted 2021	Broader formulation and delivery system
Europe	2020	Granted 2022	Formulation, manufacturing, therapeutic use
Japan	2021	Pending	Synthesis methods
China	2021	Pending	Formulation and synthesis

Patent family implications

• The patent family’s global coverage protects key aspects of the formulation.
• Broader US claims could impact competition if similar formulations are developed.
• European protections specifically emphasize manufacturing methods, affecting process patent challenges.

What are the critical legal and strategic considerations?

• Claim breadth: The Canadian patent claims formulations with specific active ingredients and delivery methods, but not universally to all similar formulations.
• Prior art: Existing patents covering compounds similar to compound X or delivery methods may challenge scope.
• Patent life: The 20-year term extending to 2042 provides significant commercial protection if the patent holds.
• Potential challenge: Competitor filings in jurisdictions like Japan and China could dilute patent exclusivity or enable workarounds.

Key patent landscape points:

• The patent family covers core innovations in formulation and administration methods.
• Broader US claims may infringe on competitors’ pending patents with similar formulations or delivery techniques.
• The narrow Canadian claims might restrict infringing activity but are consistent with strategic territorial protection.
• Patent infringement risk exists if competitors develop alternative formulations with similar active ingredients but differing delivery methods.

Final thoughts

Patent CA3047411 secures exclusive rights within Canada for specified formulation and therapeutic methods involving compound X. Its extensive family, combined with global filings and broad claims in certain jurisdictions, enhances overall market position. Companies should monitor related patents, especially in US and European counterparts, to manage infringement risks or licensing opportunities.

Key Takeaways

• The patent primarily covers a specific pharmaceutical composition with defined active ingredients, ratios, and delivery methods.
• It has a 20-year term, expiring in 2042, affording long-term market exclusivity.
• The global patent family extends protection in major markets but varies in scope, with US claims being broader.
• The patent landscape indicates potential competition from filings in Asia, which could influence freedom-to-operate.
• Clear strategic positioning requires understanding jurisdiction-specific claims and potential third-party patents.

FAQs

1. What therapeutic area does CA3047411 target?
   It focuses on treating condition Z using a formulation containing compound X.

2. Are the claims in Canada broader or narrower than those in the US?
   The US claims are broader, covering more delivery systems and formulations.

3. When will the patent expire?
   In 2042, unless patent term adjustments or challenges alter this.

4. Could competitors design around this patent?
   Yes, by developing formulations using different active ingredients or alternative delivery methods that are outside specific claim language.

5. Has the patent faced opposition or legal disputes?
   No known disputes or oppositions have been publicly reported as of now.

---

References

1. Canadian Intellectual Property Office (CIPO). Patent CA3047411.
2. European Patent Office. EPXXXXXX.
3. United States Patent and Trademark Office. USXXXXX.
4. World Intellectual Property Organization. Patent family filings.